StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Free Report) in a report issued on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.
Eagle Pharmaceuticals Stock Down 3.3 %
NASDAQ:EGRX opened at $1.19 on Tuesday. The business has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $1.70. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.81.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. DGS Capital Management LLC boosted its stake in shares of Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the period. Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals in the third quarter worth about $96,000. RBF Capital LLC grew its stake in shares of Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter worth approximately $453,000. Finally, Creative Planning bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $59,000. Institutional investors own 85.36% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
Featured Stories
- Five stocks we like better than Eagle Pharmaceuticals
- Top Biotech Stocks: Exploring Innovation Opportunities
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Why Are These Companies Considered Blue Chips?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- What is the FTSE 100 index?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
